JP2000189032A - Chemical-transpirating agent - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a chemical-transpirating agent for, e.g. insecticidal, sterilizing, insect repelling purposes, excellent in effective transpiration rate, capable of stably transpirating the chemical for a prolonged periods, simply handled, formable into a compact shape, and easily designed for the product. SOLUTION: This agent contains a chemical having a vapor pressure of 1×10-6 to 1×10-3 mmHg at 20 deg.C, supported by a fibrous holder of synthetic and/or natural fibers, fabricated to have a density of 0.05 to 1.0 g/cm3 and thickness of 0.02 to 1 mm, in such a way to secure a transpiration rate at 0.01 to 0.5 mg/h/m3. The holder can be two-dimensionally shaped, e.g. sheet, or three-dimensionally shaped, e.g. honeycomb or other shapes composed of cellular walls of lattice or net.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a drug evaporating agent, and more particularly, to a drug evaporating agent for the purpose of killing insects, controlling insects, repelling insects, inhibiting insect growth, preventing biting, aroma and deodorization, and the like. The present invention relates to a drug evaporating agent that exerts its effect by being impregnated and held in a drug holding material and released into the atmosphere at room temperature.

[0002]

2. Description of the Related Art Conventionally, drugs are continuously evaporated for a long time,
As an evaporative preparation which maintains the effect, a method in which a solid or liquid preparation is heated by a heating element to evaporate is known. As an example of the heating and evaporation method, a part of a heating evaporation body (liquid absorption core) is immersed in the medicine to suck up the medicine to the heating evaporation body, and the medicine absorbed by heating the upper part thereof. There have been proposed various methods of evaporating the heat, that is, a so-called chemical wicking type heat evaporation method. On the other hand,
-289855 discloses, as a normal temperature transpiration insect repellent,
An insecticidal and insecticidal method is disclosed in which a carrier having a through-hole and having a surface area / volume in the range of ¹ to 20 cm- ¹ holds an insecticide compound which is transpirable at room temperature. In addition, conventionally, a plate agent that kneads a highly transpirable drug such as DDVP into a vinyl chloride resin and vaporizes the drug at normal temperature to kill insects has been manufactured and sold.

[0003] However, the solvent of the chemical used in the heat evaporation method of the chemical wicking type is generally an organic solvent. For example, in the case of an insecticidal solution, a solvent such as n-paraffin containing a pyrethroid-based drug at a certain concentration is generally used. Those made of are on the market. However, hydrocarbon-based solvents have a drawback that they are very easy to burn and easily cause a fire. Further, recently, destruction of the ozone layer and air pollution on a global scale due to chlorofluorocarbons and transpirable organic compounds have become problems. For example, even a commercially available product using a chemical solution wicking method contains 90% or more of a solvent such as a hydrocarbon solvent which is originally unnecessary for insecticide purposes. Therefore, eliminating this solvent has become an important issue. Furthermore, since the upper portion of the liquid absorbent core is heated to a high temperature of 100 ° C. or higher, there is a problem that the decomposition of the drug, the deterioration of the vaporized surface of the liquid absorbent core, and clogging are apt to occur at that portion.

Further, in the case of the chemical liquid suction type, the internal pressure in the chemical liquid container fluctuates due to fluctuations in temperature, atmospheric pressure, and the like, causing liquid leakage, and contamination with the chemical liquid may occur during use or storage. In addition, it can be said that a chemical solution wicking heat evaporation method requires an unnecessary amount of heat in consideration of thermal efficiency in order to evaporate a chemical solution containing a drug. In addition, in the heating and evaporation method of the chemical liquid wicking type, immediately after the start of use, the evaporation amount of the drug is not stable, while the longer the use period, the more
It has a drawback that it is difficult to obtain a stable amount of transpiration during the use period. In addition, since the heat evaporation method requires a large amount of energy, heat evaporation using a dry battery or the like is disadvantageous in terms of energy efficiency, and there is some contrivance when producing a preparation that can be carried around.

On the other hand, it has a through hole and has a surface area / volume of 1 to 1.
Insects by holding a normal temperature transpirable insect repellent compound on a carrier in the range of 20 cm ^-1 ,
Only vaporizable drugs having a vapor pressure of 1 × 10 ⁻⁴ mmHg or more at 20 ° C. can be used, which makes it difficult to control the continuity of the efficacy and the amount of transpiration, as well as restricting the shape of the product, There is a problem in product design, such as the need to increase the size of the product when a drug that does not easily evaporate is used.
Furthermore, a plate agent that kneads a highly transpirable drug such as DDVP into a vinyl chloride resin and evaporates the drug at room temperature to kill insects is a used DDVP, which is a dramatic substance.
There is a problem in that handling is difficult in terms of safety, and when the drug is kneaded, the amount of the evaporated drug is extremely suppressed.

[0006]

SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to solve the above-mentioned problems and to provide a normal-temperature transpirable drug for a long period of time without heating with high energy as in the prior art. It is an object of the present invention to provide a stable chemical-evaporating agent capable of effectively evaporating a sufficient amount of medicine over the entire period. Further, an object of the present invention is that, during the evaporation of a drug, the drug holder coated with and impregnated with the drug may undergo decomposition of the drug and deterioration of the drug holder as in the case of the conventional heat-evaporation system of a chemical liquid suction type. Another object of the present invention is to provide a drug-evaporating agent which has an excellent effective transpiration rate, can stably evaporate a drug for a long period of time from the initial stage of use, is easy to use, has a compact product form, and is easy to design.

[0007]

According to the present invention, there is provided a fibrous material comprising synthetic fibers and / or natural fibers having a density of 0.05 to 1.0 g / cm ³ ,
A medicine having a vapor pressure of 1 × 10 ⁻⁶ to 1 × 10 ⁻³ mmHg at 20 ° C. is held on a medicine holding material processed to a thickness of 0.02 to 1 mm, and the amount of evaporation per unit space volume is reduced to 0.01. ~
There is provided a drug vaporizer characterized by being adjusted to 0.5 mg / hr / m ³ . In a preferred embodiment, a material processed into a nonwoven fabric and / or woven / knitted material and / or paper is used as the drug holding material.

[0008]

BEST MODE FOR CARRYING OUT THE INVENTION The drug evaporating agent of the present invention has a drug holding material made of a sheet-like fiber material. We have:
The sheet-like holding material that impregnates and holds the room temperature transpirable drug
Although sufficient drug transpiration was not performed for the transpiration area, and a large amount of drug loss occurred due to the relationship between the drug holding power and the knowledge that stable drug transpiration effects were difficult to obtain, we had already obtained.
As a result of intensive studies on a holding material for a transpirable drug that can solve this problem, a fibrous material composed of synthetic fibers and / or natural fibers has a density of 0.05 to 1.0 g / cm ³ and a thickness of 0.02 to 0.02 g / cm ³ . When processed into a sheet of 1 mm and coated with and impregnated with a chemical having a vapor pressure of 1 × 10 ⁻⁶ to 1 × 10 ⁻³ mmHg at 20 ° C., the amount of evaporation per unit space volume is reduced to 0 mm. It has been found that the present invention can be easily adjusted to 0.01 to 0.5 mg / hr / m ³ , and can stably evaporate the drug from the initial stage of use for a long period of time, thereby completing the present invention.

That is, the drug evaporating agent of the present invention is obtained by setting the shape of the drug holding sheet to a fibrous shape having voids inside, instead of a kneaded sheet, by setting the thickness to be small and the density to be low. The structure is such that the ventilation in the sheet becomes smooth, the air in contact with the medicine holding sheet can carry the medicine, and the medicine can be released into the atmosphere more efficiently. As a result, according to the present invention, there is provided a natural evaporation type drug evaporation method capable of efficiently evaporating the drug for a long period of time by the environmental temperature and the flow of air from the drug holding material holding various transpirable drugs. You. However, as the evaporation method of the drug evaporation agent of the present invention,
In addition to the natural transpiration method, an air-blowing method or a heating (slightly heating) method using a disposable body warmer, for example, can be applied because of the advantage of enabling efficient transpiration with little energy, and is designed to be a portable and compact product. it can.

The chemical vaporizer of the present invention does not require a power source for heating the liquid absorbent core holding the chemical unlike the conventional chemical liquid wicking type heat vaporization method, and can significantly suppress the decomposition of the chemical during the release of the chemical. And you can carry it anytime, anywhere. As a result, there is no deterioration such as clogging of the evaporation surface of the medicine holding material, and stable evaporation of the medicine over a long period of time with a high effective evaporation rate is possible. Furthermore, since the medicine evaporates uniformly from the medicine holding material without heating, the medicine evaporates stably over a long period of time, the remaining amount becomes small, and the waste of the medicine is reduced, which is economically advantageous. is there. Moreover, the thickness,
By arbitrarily setting the density, it becomes possible to easily adjust the type of the drug and the amount of the drug evaporated per unit time. Further, since there is no attachment of the drug to the surface of the device or the like, all of the evaporated drug is released into the atmosphere, and the effective evaporation rate of the drug is also improved.

[0011] The drug holding material that can be used in the present invention is required to have an ability to impregnate a required amount of drug.
A form processed into a nonwoven fabric or a woven or knitted fabric is preferable. Further, the material is desired to have chemical resistance according to the chemical used. For example, pulp as natural fiber,
Polypropylene as synthetic fiber, such as cotton, wool, hemp, silk,
Examples include polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, rayon, methacrylic resin, and glass fiber. These medicine holding materials have a thickness of 0.02 mm or more, preferably 0.03 mm or more, and a density of 0.05 g / cm ³ or more, preferably 0.1 g or more, in order to secure the holding force of the medicine.
g / cm ³ or more, and in order to facilitate the evaporation of the drug at room temperature, the thickness is 1 mm or less, preferably 0.8 mm or less, and the density is 1.0 g / cm ³ or less, preferably 0.8 g or less. / Cm ³ or less. On the other hand, when the thickness is more than 1 mm, in the case of the slightly heated evaporation method, there is a disadvantage in terms of thermal conductivity.

When these drug holding materials impregnated with a drug are formulated and used, for example, for combating adult mosquitoes, the amount of drug evaporated as the formulation is 0.01 mg / h from the viewpoint of efficacy.
r / m ³ or more, preferably 0.03 mg / hr / m ³ or more. From the viewpoint of safety and economy,
The upper limit of the amount of drug evaporation is desirably 0.5 mg / hr / m ³ or less. Evaporation area of these medicine holding materials (drug treatment area)
In the case of natural transpiration type, from potency surface 5 × 10 ⁰ cm ² /
It is desirably from m ³ or more, handleability, safety,
From the viewpoint of economy, it is desirable that the density be 1 × 10 ³ cm ² / m ³ or less. Further, in the case of the blowing type and the heating type, it is desirable that the concentration is 5 × 10 ⁻¹ cm ² / m ³ or more from the viewpoint of efficacy, and 1 × 10 ² from the viewpoint of easy handling, safety and economy.
cm ² / m ³ or less.

[0013] The normal-temperature transpiration chemicals used in the present invention include conventionally pesticides (pesticides and acaricides), fungicides, insect repellents, repellents, deodorants and fragrances (perfume,
Herbs, etc., fungicides, medicines (menthol, eucalyptus oil, etc., inhalants for trachea, colds, etc.), various drugs used alone or according to the purpose.
More than one species can be used in combination. Usually, the vapor pressure at 20 ° C. is used agents that are within the scope of ^{1.0 × 10 -6 ~1.0 × 10 -3} mmHg, among them, 1.0 vapor pressure at 20 ° C. × 10 ^-4 Compounds of mmHg or higher are preferred.

For example, when used for insecticide, various conventionally used transpirant insecticides can be used, such as pyrethroid insecticides, carbamate insecticides,
Organic phosphorus insecticides and the like can be mentioned. In general, pyrethroid insecticides are preferably used because of their high safety, and the following are particularly preferable. -Generic name: Chemical name (trade name, manufacturer) * Arlesrin; dl-3-allyl-2-methyl-4-oxo-2-cyclopentenyl dl-cis / trans-
Chrysanthemate (Pinamine, Sumitomo Chemical Co., Ltd.) * dl-d-T80-aresulin; dl-3-allyl-
2-methyl-4-oxo-2-cyclopentenyl d-
Cis / trans-chrysanthemate (Pinamine Forte, Sumitomo Chemical Co., Ltd.) * dl-dT-aresulin; dl-3-allyl-2-
Methyl-4-oxo-2-cyclopentenyl d-trans-chrysanthemate (bioarrestrin) * d · dT-aresulin; d-3-allyl-2-methyl-4-oxo-2-cyclopentenyl d- Trans-chrysanthemate (esviol) * d-d-T80-praletrin; (+)-2-methyl-4-oxo-3- (2-propynyl) -2-cyclopentenyl (+)-cis / trans-cli Santemate (Etoc, Sumitomo Chemical Co., Ltd.) * Resmethrin; 5-benzyl-3-furylmethyl d
l-cis / trans-chrysanthemate (chryslon,
Sumitomo Chemical Co., Ltd.) * dl · d-T80-resmethrin; 5-benzyl-3
-Furylmethyl d-cis / trans-chrysanthemate (Chryslon Forte, Sumitomo Chemical Co., Ltd.) * Empentrin; 1-ethynyl-2-methyl-2-pentenyl dl-cis / trans-3- (2,2 -Dimethylvinyl) -2,2-dimethyl-1-cyclopropanecarboxylate (vaporthrin, Sumitomo Chemical Co., Ltd.) * Terraresulin; dl-3-allyl-2-methyl-4-
Oxo-2-cyclopentenyl-d1-cis / trans-2,2,3,3-tetramethyl-cyclopropane camboxylate (Noxulin, Sumitomo Chemical Co., Ltd.) * transfluthrin; d-trans-2 , 3,5,6
-Tetrafluorobenzyl-3- (2,2-dichlorovinyl) -2,2-dimethyl-1-cyclopropanecarboxylate At least one or more selected from the above compounds and / or isomers and / or analogs thereof It is preferable to use the following pest control components alone or in combination as needed.

The following are examples of other pyrethroid insecticides. * Phthalsulin; N- (3,4,5,6-tetrahydrophthalimido) -methyl dl-cis / trans-chrysanthemate (neopinamin, Sumitomo Chemical Co., Ltd.) * dl · d-T80-phthalthrin; (1 , 3,4
5,6,7-hexahydro-1,3-dioxo-2-indolyl) methyl dl-cis / trans-chrysanthemate (neopinaminforte, Sumitomo Chemical Co., Ltd.) * Flamethrin; 5-propagyl-2- Furyl methyl
d-cis / trans-chrysanthemate (pinamine D,
Sumitomo Chemical Co., Ltd.) * Permethrin; 3-phenoxybenzyl dl-cis / trans-3- (2,2-dichlorovinyl) -2,2
-Dimethyl-1-cyclopropanecarboxylate (Exmin, Sumitomo Chemical Co., Ltd.) * Phenothrin; 3-phenoxybenzyl d-cis /
Trans-chrysanthemate (Smithulin, Sumitomo Chemical Co., Ltd.) * Imiprothrine; 2,4-dioxo-1- (prop-
2-ynyl) -imidazolidin-3-ylmethyl (1
R) -cis / trans-chrysanthemate (pral,
Sumitomo Chemical Co., Ltd.) * Fenvalerate; α-cyano-3-phenoxybenzyl-2- (4-chlorophenyl) -3-methylbutyrate (Sumisaidin, Sumitomo Chemical Co., Ltd.) * Cypermethrin; α-cyano -3-phenoxybenzyl dl-cis / trans-3- (2,2-dichlorovinyl) -2,2-dimethylcyclopropanecarboxylate (Agrothrine, Sumitomo Chemical Co., Ltd.) * Cyphenothrin; (±) α- Cyano-3-phenoxybenzyl (+)-cis / trans-chrysanthemate (gochelate, Sumitomo Chemical Co., Ltd.) * Ethofenprox; 2- (4-ethoxyphenyl) -2-methylpropyl-3-phenoxybenzyl Ether (trebon) * tefluthrin; 2,3,5,6-tetrafluoro-4
-Methylbenzyl-3- (2-chloro-3,3,3-trifluoro-1-propenyl) -2,2-dimethyl-1
-Cyclopropanecarboxylate * fenpropatrine; α-cyano-3-phenoxybenzyl cis / trans-2,2,3,3-tetramethylcyclopropanecarboxylate * fenfluthrin; 2,3,4,5,6 -Pentafluorobenzyl-dl-cis / trans-3- (2,2-
Dichlorovinyl) -2,2-dimethyl-1-cyclopropanecarboxylate * 1-ethynyl-2-methyl-2-pentenyl cis /
Trans-2,2,3,3-tetramethyl-1-cyclopropanecarboxylate

The following are specific examples of the organophosphorus insecticide. * Diazinone; (2-isopropyl-4-methylpyrimidyl-6) -diethylthiophosphate (diazinone) * Fenitrothion, MEP; O, O-dimethyl-O-
(3-methyl-4-nitrophenyl) thiophosphate (Sumithion) * Pyridafenthione; O, O-dimethyl-O- (3-
Oxo-2-phenyl-2H-pyridazin-6-yl)
Phosphorothioate (Offnac) * Malathion; dimethyl dicarbethoxyethyl dithiophosphate (Marathon) * Dipterex; O, O-dimethyl-2,2,2-
Trichloro-1-hydroxyethyl phosphonate * chloropyrifos; O, O-diethyl-O- (3,5
6-trichloro-2-pyridyl) -phosphorothioate * fenthion; O, O-diethyl-O- (3-methyl-4-methylthiophenyl) -phosphorothioate (vitex) * dichlorvos; O, O-dimethyl-2,2- Dichlorovinyl phosphate (DDVP) * propetanephos; O-[(E) -2-isopropoxycarbonyl-1-methylvinyl] -O-methylethylphosphoramide thioate (safrothin) * Abate; O, O, O ', O '-Tetramethyl-O,
O'-thiodi-P-phenylene phosphorothioate * Prothiophos; O-2,4-dichlorophenyl dithiophosphoric acid O-ethyl S-propyl ester (Toyothione) * Foxime; O, O-diethyl-O- (α-cyanobenzylideneamino) thio Phosphate

The following are specific examples of the insect growth inhibitor. * Pyriproxyfen; 2- [1-methyl-2- (4-
Phenoxyphenoxy) ethoxy] pyridine (Sumilab) * methoprene; 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoic acid-1-methylethyl ester * phenoxycarb; ethyl [2- (4- Phenoxyphenoxy) ethyl] carbamate * diflubenzuron; 1- (4-chlorophenyl) -3
-(2,6-difluorobenzoyl) urea * cyromazine; 2-cyclopropylamino-4,6-diamino-s-triazine * teflubenzuron; N-[[(3,5-dichloro-
2,4-difluorophenyl) amino] carbonyl]-
2,6-difluorobenzamide

The oxadiazole insecticides include the following. * Methoxadiazone; 5-methoxy-3- (2-methoxyphenyl) -O-1,3,4-oxadiazole-2
Specific examples of the (3H) -one (elemic) chloronicotine insecticide include the following. * Imidacloprid; 1- (6-chloro-3-pyridylmethyl) -N-nitroimidazolidin-2-ylideneamine (hachixan) * acetamiprolide; (E) -N ¹ -[(6-chloro-
3-pyridyl) methyl] -N ² - cyano -N ¹ - methyl acetone amidine (Mosupiran)

The following are specific examples of the bactericide. * Triflumizole; (E) -4-chloro-α, α, α
-Trifluoro-N- (1-imidazol-1-yl-
2-propoxyethylidene-O-toluidine) * hexaconazole; (R, S) -2- (2,4-dichlorophenyl) -1- (1H-1,2,4-triazol-1-yl) hexane-2 -Ol (ampyl) * sulfur (S) * TPN; tetrachloroisophthalonitrile (daconyl) * carbendazole; 2- (methoxycarbonylamino) benzimidazole (MBC) * thiofamate methyl; 1,2-bis (3 -Methoxycarbonyl-2-thioureido) benzene (Topazin M) * Procymidone; N- (3,5-dichlorophenyl)-
12-dimethylcyclopropane-1,2-dicarboximide (Sumilex) * Microbutanyl; 2-P-chlorophenyl-2- (1
H-1,2,4-triazol-1-ylmethyl) hexanenitrile (Rally) * isoprothiolane; diisopropyl-1,3-dithiolan-2-isoden-malonate (Fujiwan)

Examples of the acaricide include the following. * Kelsen; 1,1-bis (chlorophenyl) -2,
2,2-trichloroethanol * quinomethionate; 6-methylquinoxaline-2,3
-Dithiocarbonate * hexathiax; trans-5- (4-chlorophenyl) -N-cyclohexyl-4-methyl-2-oxothiazolidine-3-carboxamide

Further, fungicides and fungicides include o-phenylphenol, isopropylmethylphenol,
As fragrances such as -chloro-4-phenylphenol and thymol, various natural and artificial fragrances can be used. For example, natural fragrances of animal or vegetable origin, or hydrocarbons, alcohols, phenols, aldehydes, ketones, lactones, oxides And artificial flavors such as esters.

Specific examples of the repellent include the following. * N, N-diethyl-m-toluamide (diet) * dimethyl phthalate * dibutyl phthalate * 2-ethyl-1,3-hexanediol * 1,4,4a, 5a, 6,9,9a, 9b-octahydro Dibenzofuran-4a-carbaldehyde * di-n-propyl isosincomeronate * p-dichlorobenzene * di-n-butylsuccinate * capric acid diethylamide * N-propylacetanilide * β-naphthol * camphor

The following are examples of natural essential oils and / or components thereof. * Citral, citronellal, citronellol, eugenol, methyleugenol, geraniol, cinamic aldehyde, linalool, perilaldehyde, nepetalic acid, methylheptenone, decylaldehyde,
Myrcene, geraniol acetate, thymol, limonene, cineol, pinene, cimene, terpinene, sabinene, elemen, cedren, elemol, bidolol, cedrol, hinokitiol, tuyaprisin, tropoloid, hinokitin, tsuyosen, borneol, camphene, terpineol, terpinyl diester , Farandrene, cineole, potassium olefin, vanillin,
Furfural, furfuryl alcohol, pinocalveol, pinocarbone, myrtenol, verbenone, carvone, oidesmol, piperiton, tsuen, funkyalcohol, methylanthranilate, bisabolene, bengaptor, nonylaldehyde, nonyl alcohol,
Nootkatone, octylaldehyde, linalyl acetate, geranyl acetate, nerolidol, ocimene, methyl anthranilate, indole, jasmon, benzaldehyde,
Plegon, etc. * The above isomers and / or derivatives * Essential oil containing at least one or more selected from the above

Further, the following synergists can be used in admixture with other drugs. * Butyl carbitol 6-propyl-piperonyl ether (trade name piperonyl butoxide) * Octachlorodipropyl ether (trade name S-42)
1) * Isobornyl thiocyanate acetate (trade name IBT)
A) * N-octylbicycloheptenecarboximide (trade name sinepiline 222) (2-ethylhexyl) -1-isopropyl-4-methylbicyclo (2,2,2) oct-5-ene-2,3-
Dicarboximide (trade name Sinepirin 500)

In addition, an antioxidant can be used in combination to prevent the decomposition of the drug and the clogging of the drug holding material accompanying the decomposition of the drug. Antioxidants suitable for the present invention include 2,2'-methylenebis (4-ethyl-6-t-butylphenol) and 2,2'-methylenebis (4-methyl-6-t-
Butylphenol), 4,4'-methylenebis (2-methyl-6-t-butylphenol), 4,4'-butylidenebis (3-methyl-6-t-butylphenol),
4,4'-thiobis (3-methyl-6-t-butylphenol), 4,4'-methylenebis (2,6-di-t-
Butylphenol), stearyl-β- (3,5-di-
t-butyl-4-hydroxyphenyl) propionate, 1,3,5-trimethyl-2,4,6-tris (3,5-di-t-butyl-4-hydroxybenzyl)
Benzene, 1,1,3-tris (2-methyl-5-t-
Butyl-4-hydroxyphenyl) butane, tetrakis [methylene (3,5-di-tert-butyl-4-hydroxycinnamate)] methane, BHT, BHA, 3,5-di-tert-butyl-4-hydroxyanisole, Mercaptobenzimidazole, dilauryl-thio-di-propionate, 2-t-butyl-4-methoxyphenol, 3
-T-butyl-4-methoxyphenol, 2,6-di-
t-butyl-4-ethylphenol, α-tocopherol, ascorbic acid, erythorbic acid, 1,1-bis (4-hydroxyphenyl) cyclohexane, octadecyl-3,5-di-t-butyl-4-hydroxyhydrocinnamate , Phenyl-β-naphthylamine, N, N
-Diphenyl-p-phenylenediamine, 2,2,4-
Trimethyl-1,2-dihydroquinoline polymer, 6-
Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline, 2,2-thiobis (4-methyl-6-tert-butylphenol), 3,5-di-tert-butyl-4-hydroxy-benzylphosph Phonate-diethyl ester, calcium bis (3,5-di-t-butyl-4-hydroxybenzylphosphonate) calcium; polyethylene wax, octylated diphenylamine, tris [2-
(3 ', 5'-Di-tert-butyl-4'-hydroxyhydro-cinnamoyloxyl) ethyl] isocyanurate, tris- (4-tert-butyl-2,6-dimethyl-3)
-Hydroxybenzyl) isocyanurate, 3,9-bis [1,1-di-ethyl-2- (β- (3-t-butyl-4-hydroxy-5-methyl-phenyl) propionyloxy) ethyl] -2 , 4,8,10-Tetraoxaspiro [5.5] undecane, ditridecyl-3,3 '
-Thiodipropionate, dimyristyl-3,3'-thiodipropionate, distearyl-3,3'-thiodipropionate and the like.

The above antioxidants can be used alone or in combination of two or more.
As the method of addition, it is conceivable to add the compound to the pest control liquid or to the obtained holding material, but it is optional. Further, as an antioxidant generally called a peroxide decomposer, dilauryl thiodipropionate (DL)
TP) and distearyl thiodipropionate (DST)
P) may be used in combination with the antioxidant. Furthermore, paraffins, glycols, ethers and waxes can be used to control the transpiration.

Further, by using an ultraviolet absorber such as para-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone or benzotriazole as an ultraviolet absorption inhibitor, the light resistance during storage and use can be further improved. it can.

In order to prepare a chemical solution, a solvent can be used if necessary. Solvents may be aqueous or oily, and include water, alcohols such as methyl alcohol and ethyl alcohol, esters such as diethyl phthalate, isopropyl myristate and butyl stearate, and aliphatic hydrocarbons such as hexane, kerosene and paraffin. Kind,
Examples thereof include aromatic hydrocarbons such as benzene and xylene, and ethers such as ethylene glycol and ethylene glycol diethyl ether.

When the agent of the present invention is prepared as a pesticide, mosquitoes such as Culex pipiens, Culex pipiens, Aedes albopictus, Aedes albopictus, etc.
Cockroaches such as German cockroaches, black cockroaches, cockroach cockroaches, brown cockroaches, yamato cockroaches, flies such as house flies, gypsophila, sentinia flies, kebukakuro flies, yellow flies and flies,
Drosophila such as Drosophila and Drosophila,
Fleas such as cat flea, dog flea, and human flea, clothing pests such as Iga, Koiga, Himematsubuushimushi, Himamarukabuushimushi, storage insect pests such as Noshime-Darameiga, Kokunusutomodoki, Kokuzou, Marukamushi, Shibamemushi, etc. It is effective against various pests such as lice and lice, and can be used in various scenes such as ordinary households, warehouses, factories, and restaurants.

The method of applying the evaporative agent to the holding material is not particularly limited, but a liquid coating method such as drop coating, impregnation coating, spray coating, a liquid printing method, a brush coating method, or the like can be employed. It is also possible to store the transpiring drug in a liquid bottle, immerse a part of the drug holding material in the drug solution, absorb the drug solution, and supply it to the evaporation unit. As the form of the holding member, any of a two-dimensional structure such as a sheet shape and a three-dimensional structure such as a three-dimensional structure formed of cell walls such as a honeycomb shape, a lattice shape, and a mesh shape is possible. In the case of a two-dimensional structure such as a sheet, not only a single sheet material cut into a desired shape but also a sheet-like form in which this is layered is included. Also, a large number of through-holes having an arbitrary pattern such as a lattice shape or a mesh shape can be formed in the sheet material. on the other hand,
The three-dimensional structure includes spherical, elliptical spherical, cylindrical, cylindrical, conical, quadrangular pyramid (pyramid), cubical,
In addition to a three-dimensional structure such as a rectangular parallelepiped, a three-dimensional structure obtained by processing a sheet material into an artificial flower, a paper crane, a streamer, or the like can be given. Hereinafter, some examples of the three-dimensional structure will be described with reference to the accompanying drawings.

FIGS. 1 and 2 show an embodiment of a honeycomb structure. FIG. 1 shows a state where a honeycomb structure 1 is divided into two parts.
FIG. 2 shows the overall appearance. The honeycomb structure 1 is configured as a generally spherical structure in which the cells 3 surrounded by the cell walls 2 are arranged perpendicular to the central axis X and parallel to the outer peripheral surface of the sphere, and An internal space S is formed in the center. Therefore, almost all of the cells 3 are in communication with the internal space S, so that the flow of air is not suppressed. The medicine is impregnated and held in the cell wall 2 by an arbitrary method such as a spray method, an immersion method and the like. In this way, by forming a three-dimensional structure with honeycomb (or lattice, mesh, etc.) cell walls made of a material capable of impregnating and holding a drug, and forming a space therein, Ventilation to each cell is promoted, whereby the amount of active ingredient evaporating is increased, and the active ingredient can be stably evaporated over a long period of time.

The honeycomb structure 1 shown in FIGS. 1 and 2
When laminating a half-divided ring-shaped sheet (a ring-shaped portion on the right (or left side) of the central axis X in FIG. 1), a band-shaped adhesive portion A is formed according to a desired size of each cell. In addition, a large number of sheets are laminated in parallel at an appropriate interval while being sequentially bonded so as to be in a stepped state between the previous layer and the subsequent layer, and the edge of the obtained laminate on the side of the central axis X is bonded, This can be performed by expanding the laminate and bonding the sheets on both sides, thereby obtaining a honeycomb structure having a spherical shape as a whole as shown in FIG. Alternatively, a semicircular sheet (or a rectangular sheet) is laminated while being adhered in the same manner as described above, and a semicircular portion (in the case of using a rectangular sheet, the outer periphery is further reduced when the rectangular sheet is used) corresponding to the internal space of the obtained laminate. By punching out the outermost part), a half-split ring-shaped laminate can be manufactured. Further, by arranging the band-shaped adhesive portions A radially from the center of the sphere, all the cells communicate with the internal space, and are arranged radially from the internal space toward the spherical outer peripheral surface. It can also be a body.

The drug carrier having a three-dimensional structure according to the present invention comprises:
The present invention is not limited to the honeycomb structure as shown in FIGS. 1 and 2, and can be configured in various structures and forms. For example, when the bonding portion A in FIG. 1 is narrowed, the cells become lattice cells. Further, sheets having a large number of through-holes can be laminated so as to have an arbitrary pattern such as a lattice shape or a mesh shape. Furthermore, the appearance of the three-dimensional structure,
The shape is not limited to a spherical shape as shown in the figure, and may be an arbitrary three-dimensional shape such as a cylinder, a cube, a pyramid, or another polygon.

The three-dimensional structure having a large number of cell walls for holding the room-temperature evaporative drug can be formed into a multi-layered structure of at least two layers spaced apart from each other at a predetermined interval or excellent in convenience of use. It can be configured to be freely foldable. In particular, by forming a three-dimensional structure having a multi-layered structure of at least two inner and outer layers separated from each other at a predetermined interval so as not to be in contact with each other, it is possible to use the present invention in various forms. In the first mode of use, the outermost layer of the drug carrier is a protective layer that does not retain an active ingredient. As a result, the outermost protective layer functions as a barrier layer that prevents direct irradiation of light or dust from adhering to the inner active ingredient holding layer, and significantly reduces phenomena such as decomposition of active ingredients and suppression of evaporation. . Further, by using the outermost layer as a protective layer, the medicine impregnated and held in the medicine holding body does not adhere to hands or the like, which is advantageous in preventing loss of active ingredients and improving safety. Such an effect can also be obtained by arranging the medicine holder in a freely foldable manner.

A second mode of use is to allow each layer of the multiplex structure to hold room temperature transpirable drugs having different actions or vapor pressures and to exert several effects simultaneously. An advantage of such a support structure of the present invention is that the active ingredient holding layer has a multi-layer structure in which the active ingredient holding layers are not in contact with each other, so that active ingredients having different actions or vapor pressures can be held, and each action can be sufficiently performed. It is a point that can be demonstrated. In the case where multiple active ingredients are held in a single-structured support, for example, when a mixture of a plurality of substances having different vapor pressures is used, the transpiration of the easily vaporizable substance having a high vapor pressure becomes difficult transpiration having a low vapor pressure. Phenomena such as being suppressed by the active substance occur, and the performance cannot be sufficiently exhibited. On the other hand, if it is a support structure where each layer of the multi-layer structure holds a normal temperature transpirable drug with a different action or vapor pressure, a sustained component that stably exerts its effect over a long period of time, and a large effect mainly in the initial stage of use It is possible to reliably evaporate both of the quick-acting components exhibiting the above. Also, when a plurality of active ingredient holding layers are arranged concentrically from the center of the structure, the inside is poorly ventilated and the amount of transpiration is reduced. It is possible to maintain the sex component and adjust the amount of evaporation of both components. As a result, the effect can be maintained for a long period of time, and several effects can be simultaneously exhibited to enhance the effect. In addition, even in such a use form, for example, a three-dimensional structure having a multi-layer structure of at least three layers, the outermost layer is a protective layer that does not hold a normal temperature transpirant, and the action or vapor pressure of each of the inner layers is different. Although a normal-temperature transpirable drug can be retained, an embodiment in which an easily transpirable component having a high vapor pressure is retained in the outermost layer and this component is vaporized and then used as a protective layer is also possible.

One embodiment of the honeycomb structure having a multi-layer structure is shown in FIGS. FIG. 3 shows a state where the honeycomb structure 1 is divided into two parts, and FIG. 4 shows a state where the honeycomb structure 1 is folded. In addition,
The overall appearance is the same as FIG. The honeycomb structure 1 has a generally spherical structure in which the cells 3 surrounded by the cell walls 2 are arranged perpendicular to the central axis X and parallel to the outer peripheral surface of the sphere. , A double structure of the outer layer 4 and the inner layer 5, wherein gaps 6 are formed at predetermined intervals between the inner and outer layers so as not to be in direct contact with each other, and an inner space S is formed at the center thereof. . Therefore, each cell 3
Is almost in communication with the internal space S so that the flow of air is not suppressed. The drug is impregnated and held in the cell wall 2 of the inner layer 5 by an arbitrary method such as a spraying method or an immersion method. On the other hand, the outer layer 4 has no treatment and does not hold a drug, and functions as a protective layer of the inner layer 5 which is an active ingredient holding layer. May be impregnated and retained.

The honeycomb structure 1 shown in FIG. 3 and FIG.
Is manufactured on a semicircular support sheet 7, a plurality of half-divided small ring-shaped and large ring-shaped drug holding sheets constituting the inner layer 5 and the outer layer 4 (right side of the central axis X in FIG. 1 ( When the large and small ring-shaped portions (on the left side) are arranged and laminated at predetermined intervals as shown in FIG. 3, the band-shaped adhesive portions A are arranged in parallel at appropriate intervals according to the desired size of each cell. Moreover, a large number of sheets are laminated while being sequentially bonded so as to be in a stepped state between the preceding holding sheet and the following holding sheet, and the edge of the obtained laminated body on the central axis X side is bonded, and finally the other surface is formed. The bonding is performed by bonding the support sheet 8 described above to obtain a laminate as shown in FIG. In use, by opening the support sheets 7 and 8 on both sides to expand the laminate and joining the support sheets 7 and 8 on both sides, a generally spherical honeycomb structure as shown in FIG. 2 can be assembled. it can. The joining of the support sheets 7 and 8 on both sides
Attach a double-sided adhesive tape to a predetermined portion of the edge of one of the support sheets (7 or 8), or apply an adhesive,
It can be performed by an appropriate method. By arranging the band-shaped adhesive portions A radially from the center of the sphere, all the cells communicate with the internal space S, and the honeycombs are radially arranged from the internal space toward the spherical outer peripheral surface. It can also be a structure.

In order to promote the evaporation of the medicine, it is preferable to use a holding sheet having a small basis weight, in which case the sheet is generally weak in stiffness in many cases. Therefore, in order to maintain the shape of the entire holding body, it is preferable to select a material having a strong stiffness for the support sheet. A support sheet with a strong stiffness generally has a large basis weight, and the amount of transpiration may be suppressed when the drug is transferred. As means for avoiding this, it is conceivable to provide a barrier layer between the support sheet and the drug holding sheet, and specifically,
A method of laminating a gas barrier film, aluminum foil, or the like on the support sheet is preferable.

FIG. 5 shows a modification of the honeycomb structure shown in FIGS. In this honeycomb structure 1a, a gap 6a between the outer layer 4a and the inner layer 5a and a gap 11 communicating with the internal space S are formed in the entire inner layer 5a in a direction perpendicular to the central axis X. 3 and 4 in that the inner layer 5a is divided into 12-1 layers and 12-2 layers, but other configurations are the same. FIG. 5 shows the support sheets 7a and 8a on both sides opened 180 degrees. On the other hand, FIG. 6 shows an embodiment of a honeycomb structure 1b having a three-layer structure. That is, it has a multiplex structure in which the intermediate layer 13 is disposed between the outer layer 4b and the inner layer 5b, and the gaps 6b, 14 are provided between the respective layers.
Is different from the honeycomb structure shown in FIGS. 3 and 4. FIG. 6 also shows support sheets 7 on both sides.
b and 8b are shown opened 180 degrees. In the case of this honeycomb structure 1b, it is preferable that the outer layer 4b is a protective layer that does not hold an active component, and that the intermediate layer 13 and the inner layer 5b are impregnated and held with two types of active components having different functions or vapor pressures.

FIGS. 7 to 9 show another embodiment of the drug carrier of the present invention. This honeycomb structure 1c is
It has an outer layer 4c and an inner layer 5c of a honeycomb structure which are separated from each other by a gap 6c so as not to be in direct contact with each other, and has a substantially elliptical spherical three-dimensional shape as a whole. Unlike the honeycomb structure shown in FIGS. 1 to 6, no space is formed inside. One end of each of the support sheets 7c and 8c on both sides is protruded to form a grip 15. This honeycomb structure 1c
In order to increase the amount of transpiration of the impregnated and held active ingredient, assembling as shown in FIG.
5 can be used by shaking it. However, as shown in FIG. 10, one end of the elastic linear member 16 is fixed to the grip portion 15, and the other end is fitted into the support portion 18 of the support base 17, and FIG.
As shown in FIG. 0, the supported honeycomb structure 1c can be used while pushing and oscillating and vibrating slowly as a whole. Alternatively, the grip portion 15 may be attached to a vibration device or an opening / closing device (not shown) via an appropriate connecting member as needed, and the honeycomb structure 1c may be used while being vibrated or opened / closed.

FIGS. 11 and 12 show modifications of the honeycomb structure shown in FIGS. 7 to 9, respectively, in a folded state. In the case of the honeycomb structure 1c shown in FIGS.
Since the two support sheets 7c and 8c are superimposed (FIG. 9)
), The communication state of the gap 6c is interrupted at this portion, and the ventilation state of each cell 3 may not be sufficient. Therefore, in the honeycomb structure 1d shown in FIG. 11, a plurality of (three in the illustrated example) vent holes 1 are provided at positions corresponding to the gaps 6d of the support sheets 7d (8d not shown) on both sides.
9 is formed so that both sides of the superposed support sheets 7d and 8d communicate with each other. On the other hand, in the honeycomb structure 1e shown in FIG.
A substantially semicircular notch 20 is provided at an intermediate portion of one side (center axis) of the support sheets 7e (8e not shown) on both sides and a number of sheets constituting a cell wall stacked therebetween.
The notch 20 forms an internal space at the center of the honeycomb structure 1e when assembled.

The basis weight of the multiple structure was 10 g / m ²
By adjusting the amount in the range of from 200 g / m ² to 200 g / m ² , it is possible to further arbitrarily control the evaporation amount of the active ingredient depending on the structure, that is, the impregnation site. For example, when it is desired to impregnate active ingredients having different vapor pressures and evaporate the same amount in a holder having a structure shown in FIG.
A part having a basis weight of 20 g / m ² was used for the portion (-1 portion), and an easily transpirable component holding portion (for example, the portion of 12-2) was used.
By using a sheet-like member having a basis weight of 70 g / m ^2, the same amount of transpiration can be obtained without changing the area.

Further, the above-mentioned medicine holding body is left at the place of use (in the case of a foldable medicine holding body, it is left open), and the held normal temperature transpirable active ingredient is kept at room temperature. Although it can be used in a state where it is allowed to evaporate naturally, it can also be used in a mode in which the evaporation of the active ingredient is forcibly promoted. That is, the medicine holder as described above can be vibrated or opened and closed to promote the evaporation of the active ingredient, and in the case of a three-dimensional structure in which an internal space is formed, a fan is provided in the internal space of the medicine holder. It can also promote the evaporation of the active ingredient. Some examples of apparatuses for performing such a drug evaporation method will be described with reference to the drawings.

FIG. 13 shows an example of a mode in which the honeycomb structure is entirely vibrated in order to promote ventilation. This drug evaporation device has a double structure of an outer layer 4f and an inner layer 5f separated by a gap 6f, similarly to the honeycomb structure shown in FIGS. 3 and 4, and has a space S formed therein. It comprises a structure 1f and a driving device 21 arranged in the internal space 7f. Note that the honeycomb structure 1f
Is shown with the support sheets 7f, 8f on both sides opened 180 degrees. As shown in FIG. 14, the drive device 21 includes a drive shaft 22, a pendulum 23 having one end rotatably attached to the drive shaft 22 and a permanent magnet 24 attached to the other end, and a pendulum 23. And an electromagnet 25 disposed in close proximity to the swing locus. Reference numeral 26 denotes an electromagnet 25
Battery to excite the battery. The drive shaft 22 is shown in FIG.
As shown in FIG. 3, the driving device is disposed in the gap between the center-axis-side edge portions of the supporting sheets 7f and 8f of the honeycomb structure 1f facing each other, and by joining the two supporting sheets 7f and 8f, the driving device is in the internal space S. Housed within.

In the case of this chemical vaporizer, the repetition of the excitation and the demagnetization of the electromagnet 25 causes the pendulum 23 to oscillate, thereby driving the honeycomb structure 1f as a whole and promoting ventilation. Impregnating the cell wall
Evaporation of the retained active ingredient is promoted. The switch (not shown) of the vibration device 21 is connected to the honeycomb structure 1.
By leading it out of f, the honeycomb structure 1f can be made to vibrate when desired. As a power source for driving the entire medicine holding body, in addition to a pendulum using an electromagnet and a permanent magnet as in the above embodiment, a motor, a mainspring, rubber, and the like can be considered. However, it is convenient when long-term use is considered. A motor or an electromagnet pendulum is preferable in terms of properties, and an electromagnet pendulum is preferable in terms of power consumption when a battery or the like is used.

FIG. 15 shows an embodiment of a chemical vaporizer using a fan to forcibly promote ventilation. The forced vaporization type drug evaporation device shown in FIG. 15 shows an example in which a hollow columnar honeycomb structure 1g having an internal space S is used. The honeycomb structure 1g disposed on the container 36 is configured such that each of the honeycomb-shaped cells 3 surrounded by the cell walls 2 communicates from the internal space S to the outer periphery. Are rotatably arranged. The fan 30 has a structure in which a ring-shaped blade fixing member 32 is fixed to an upper end of four blades 31 arranged symmetrically in parallel, and a rotating plate 33 is fixed to a lower end. It is attached to a rotating shaft 34 of a motor 35 housed in a container 36. The power supply method to the motor 35 may be, for example, either an internal power supply method in which a dry battery is accommodated in the container 36 or an external power supply method in which a wiring cord is connected.

In the case of the above-mentioned chemical vaporizing apparatus, when a switch (not shown) is turned on to drive the motor 35 and the fan 30 is rotated, the air flowing from the upper portion is directed by the fan 30 from the internal space S to the outer periphery. Since the inside of each cell 3 can be forcibly ventilated, the transpiration of the effective component impregnated in the honeycomb structure 1g can be promoted, and the transpiration amount of the active component can be determined by the wind power (rotation speed, blades) of the fan. Size, number, shape, etc.). In addition,
In practice, an outer shell container provided with one or more vents is necessary to avoid contact with the fan and the medicine holder and foreign matter contamination. In addition, a method in which the entire device is reversed to avoid contact with the fan and air is taken in from the lower portion is also conceivable.

FIG. 16 shows another embodiment of a chemical vaporizer using a fan to forcibly promote ventilation. The forced vaporization type drug evaporation device shown in FIG. 16 has a double columnar honeycomb structure 1h having an inner space S and having a double structure of an outer layer 4h and an inner layer 5h separated through a gap 6h. An example is shown. The honeycomb structure 1h disposed on the container 36 is configured such that, in each of the outer layer 4h and the inner layer 5h, the honeycomb-shaped cells 3 surrounded by the cell walls 2 communicate from the internal space S to the outer periphery. In the internal space S, a fan 30 is rotatably disposed as in the embodiment shown in FIG.

The chemical vaporization system for forcibly promoting aeration is not limited to the one shown in FIGS. 15 and 16, but may have various structures. For example, the honeycomb structures 1g and 1h can be any polygonal pillars such as a cube, a pentagonal pillar, or a hexagonal pillar, in addition to a hollow cylindrical body. Also, the spherical honeycomb structure shown in FIGS. 1 to 6 has a hemispherical structure obtained by dividing the honeycomb structure into half, and the fan is disposed in the internal space. For example, the fan 30 shown in FIGS. A dome-shaped structure arranged on the container 36 so as to cover it can also be used. In this case, an intake hole may be formed in the container 36 or the lower rotating plate 33 so that air flows into the internal space of the honeycomb structure from below. Further, the honeycomb structures 1g and 1h are
It can also be manufactured from a sheet in which a large number of through holes are formed so as to have an arbitrary pattern such as a lattice shape or a mesh shape.

When the fan is installed in the space provided inside the honeycomb structure as described above, the amount of the transpiration of the active ingredient depends on the wind power of the fan, more than the volume of the provided internal space and the opening area of the cell. You. When securing a high amount of active ingredient transpiration, the wind speed at the outlet of the wind of the three-dimensional structure is 0.1%.
It is preferably at least m / sec. As a power source for driving the fan, a motor, a mainspring, rubber or the like can be considered, but it is preferable to use a motor in order to obtain a stable effect over a long period of time. The material of the fan is not particularly limited, such as plastic and cardboard, but it is preferable to select a lightweight material from the viewpoint of improving energy efficiency.

As a constituent material of the holding member, as described above, a fibrous material made of synthetic resin and / or natural fiber has a density of 0.05 to 1.0 g / cm ³ and a thickness of 20 to 800 μm.
As long as it is processed into m, all can be used and may be appropriately selected according to the active ingredient. In particular, by making the material of the outermost layer transparent, it is possible to make the inner active ingredient holding layer easier to see. For example, when the active ingredient holding layer has an indicator function using a dye that develops with the evaporation of the active ingredient, the change in color tone can be easily seen. Such a drug-effect-indicating composition having an indicator function is, for example, an electron-donating color-forming organic compound (dye)
And by allowing the transpirant desensitizing agent to further exist in the developer and the developer, while the transpirable desensitizing agent remains sufficiently, the desensitizing effect of the above agent exceeds the effect of the developer and suppresses color development. However, when the drug evaporates and the residual rate decreases, the reaction between the color developer and the electron-donating color-forming organic compound starts, the color starts to be formed, and the drug completely evaporates and no longer remains. This is an application of a color-forming principle that sometimes exhibits a color tone specific to an electron-donating color-forming organic compound to a medicinal effect display. Therefore, the above reaction process corresponds to the process of transpiring the transpiring desensitizing drug, and the change in the color tone of the composition makes it possible to visually and accurately know the residual state of the transpiring desensitizing drug and the end point thereof. Such a drug efficacy indicating composition is already known and has been applied in various fields such as room temperature transpirable desensitizing insecticides and insect repellents, and therefore detailed description thereof is omitted (for example, Patent No. 2607361). No.).

FIG. 17 shows an embodiment of an automatic take-up roll screen type chemical vaporizer. This device 4
Reference numeral 0 denotes a structure in which a sheet-like drug holding body 45 impregnated with and holding a transpirable drug is wound around a roll 42 rotatably disposed in a hollow cylindrical body 41. The lower edge protrudes from a slit-shaped opening (not shown) formed in the lower part of the hollow cylindrical body 41 in the axial direction. A reinforcing sheet 46 is adhered to the lower edge of the medicine holding body 45, and when the medicine holding body 45 is entirely housed inside the hollow cylindrical body 41, the reinforcing sheet 46 comes into close contact with the slit-shaped opening. It is configured to seal and prevent drug evaporation.

One end of the roll 42 (left end in FIG. 17)
The hollow cylindrical member is connected via a ratchet mechanism so that the medicine holding body 45 does not return to its original position when the medicine holding body 45 is pulled down by a predetermined length with the gripping member 47 attached to the reinforcing sheet 46. When the ratchet release button 43 is pressed, the medicine holder 45
Returns to the original state of being entirely wound around the roll 42 by the automatic winding mechanism. Therefore, when not in use, in addition to blocking the drug evaporation by storing the drug holding body 45 in the hollow cylindrical body 41, by a length corresponding to the desired amount of evaporation,
It is possible to adjust the transpiration such that the medicine holder 45 is pulled down to be exposed. This is one of the very important functions for this formulation, which is difficult to control transpiration. Reference numeral 44 denotes a hanging member for suspending the device on a wall or the like.

[0054]

EXAMPLES The present invention will be specifically described below with reference to examples and comparative examples, but the present invention is not limited to the following examples.

Example 1 Teralesulin was dissolved in hexane at 3.125% (w / v), and 16 ml of the solution was coated with Dengri base paper (18.7 g of basis weight).
/ M ² , manufactured by Shirakawa Paper Co., Ltd.) with a surface area (one side) of 100
It was applied to a 0 cm ² dendri (a spherical honeycomb structure shown in FIGS. 1 and 2) and air-dried to obtain a test agent. This was used for five tests.

Example 2 Teralesulin was dissolved in hexane at 3.125% (w / v), and 80 ml of the solution was applied to 5000 cm ² shoji paper (trade name: Hi-Pac, manufactured by MOLZA Co., Ltd.) and air-dried. A reagent was obtained.

Example 3 Teralesulin was dissolved in hexane at 3.125% (w / v), and 20 ml of the solution was applied to 1243 cm ² of A3 size high-quality paper (product number TPCCA3) and air-dried to obtain a test agent. This was used for the four-sheet test.

Example 4 Teralesulin was dissolved in hexane at 3.125% (w / v), and 4 ml of the solution was applied to a filter paper having a diameter of 18.5 cm (Toyo Filter Paper No. 5A) and air-dried to obtain a test agent. Was. This was used for a 20-sheet test.

Example 5 Teralesulin was dissolved in hexane at 1% (w / v), and 250 ml of the solution was applied to a 5000 cm ² polypropylene nonwoven fabric (product number RN2020, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 6 Teralesulin was dissolved in hexane at 1% (w / v), and 250 ml of the solution was applied to a 5000 cm ² nonwoven fabric made of polypropylene (product number RN2040, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 7 Teralesulin was dissolved in hexane at 1% (w / v), and 250 ml of the solution was applied to a 5000 cm ² polypropylene nonwoven fabric (product number RW2100, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 8 Terraresulin was dissolved in hexane at 1% (w / v), and 250 ml of the solution was applied to a 5000 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 9 d · dT-Allethrin (esviol) was dissolved in hexane at a concentration of 0.2% (w / v), and 1000 ml of the solution was dissolved in hexane.
000cm ² polypropylene non-woven fabric (Model RW20
40, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried to obtain a test agent.

Example 10 dl · d-T80-Allethrin (pinamine forte) was dissolved in hexane at a concentration of 0.2% (w / v).
ml was applied to a 30000 cm ² polypropylene nonwoven fabric (product number RW2040, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried to obtain a test agent.

Example 11 dd-T80-Praletrin in hexane at 0.04%
(W / v) dissolved, and 1250 ml thereof was dissolved at 25000 c
polypropylene nonwoven fabric (product number RW2040, Idemitsu Petrochemical Co., Ltd.) in m ² air dried was applied to give the test preparation.

Example 12 Empentrin was dissolved in hexane at 3% (w / v).
500 ml of the nonwoven fabric is made of 10,000 cm ² of polypropylene nonwoven fabric (product number RW2040, manufactured by Idemitsu Petrochemical Co., Ltd.)
And air-dried to obtain a test agent.

Example 13 Transfluthrin was dissolved in hexane at a concentration of 1% (w / v), and 100 ml of the solution was applied to a 2000 cm ² polypropylene nonwoven fabric (product number RW2040, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. A reagent was obtained.

Example 14 Terrareslin was dissolved in hexane at 15.625% (w / v), and 16 ml of the solution was dissolved in a surface area (one side) of 1000 cm ^2.
Dengre base paper (having a basis weight of 18.7) processed into an accordion-shaped dengue (a cylindrical honeycomb structure shown in FIG. 15).
g / m ² , manufactured by Shirakawa Paper Co., Ltd.) and air-dried to obtain a test agent. As shown in FIG. 15, this was mounted on a fan-type blower that generates a wind having a wind speed of 1.5 liter / second and used.

Example 15 Transfluthrin in hexane at 15.625% (w /
v) Dissolve, and dissolve 6.4 ml of the solution with a surface area (one side) of 400
Dengri base paper (basis 1) processed into accordion-shaped dengris (columnar honeycomb structure shown in FIG. 15) of cm ²
(8.7 g / m ² , manufactured by Shirakawa Paper Co., Ltd.) and air-dried to obtain a test agent. As shown in FIG.
It was used by being attached to a fan type blower that generates a wind of 5 liters / second.

Example 16 Teralesulin was dissolved in hexane at 3.125% (w / v), and 16 ml of the solution was processed into a circular dendri with a surface area (one side) of 1000 cm ² (spherical honeycomb structure shown in FIGS. 1 and 2). Dengri base paper (basis weight 18.7g /
m ² , manufactured by Shirakawa Paper Co., Ltd.) and air-dried to obtain a test agent.

Example 17 Teralesulin was dissolved in hexane at 1% (w / v), and 50 ml of the solution was applied to a 1000 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 18 Empentrin was dissolved in hexane at 3% (w / v).
100 ml thereof was applied to a 2000 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried to obtain a test agent.

Example 19 Transfluthrin was dissolved in hexane at 1% (w / v), and 20 ml of the solution was applied to a 400 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. A reagent was obtained.

Example 20 Teralesulin was dissolved in hexane at 3.125% (w / v), and 3.2 ml of the solution was treated with Dengue base paper (having a basis weight of 18.7).
g / m ² , manufactured by Shirakawa Paper Co., Ltd.) with a surface area (one side) of 20
It was applied to a 0 cm ² dendri (a spherical honeycomb structure shown in FIGS. 1 and 2) and air-dried to obtain a test agent.

Example 21 Terrareslin was dissolved in hexane at 1% (w / v), and 10 ml of the solution was applied to a 200 cm ² nonwoven fabric made of polypropylene (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. I got

Example 22 Empentrin was dissolved in hexane at 3% (w / v).
20 ml thereof was applied to a 400 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried to obtain a test agent.

Example 23 Transfluthrin was dissolved in hexane at 1% (w / v), and 4 ml of the solution was applied to an 80 cm ² polypropylene nonwoven fabric (product number RW2150, manufactured by Idemitsu Petrochemical Co., Ltd.) and air-dried. A reagent was obtained.

Comparative Example 1 Polypropylene (density: 0.9 g / cm ³ ) kneaded with 5.56% by weight of terrareslin was stretched into a sheet having a thickness of 0.1 mm and cut into 5000 cm ² to obtain a test agent. Was.

COMPARATIVE EXAMPLE 2 1.11 w of d · dT-aresulin (esviol)
t% kneaded polypropylene (density 0.9g / c
m ³ ) was stretched into a sheet having a thickness of 0.1 mm, which was cut into 20,000 cm ² to obtain a test agent.

Comparative Example 3 Polypropylene (density 0.9 g / cm ³ ) kneaded with 0.22% by weight of d · d-T80-praletrin was stretched into a sheet having a thickness of 0.1 mm.
The sample was cut into cm ² to obtain a test agent.

Comparative Example 4 Polypropylene (density 0.9 g / cm ³ ) kneaded with 5.56 wt% of terrareslin was stretched into a sheet having a thickness of 0.1 mm, and cut into 1000 cm ² to obtain a test agent. Was.

Comparative Example 5 Polypropylene (density 0.9 g / cm ³ ) kneaded with 5.56 wt% of terrareslin was stretched into a sheet having a thickness of 0.1 mm, and the sheet was cut into 200 cm ² to obtain a test agent. Was.

Test Example 1 Each of the test agents shown in Table 1 was hung on the central ceiling of an 8 tatami (33 m ³ ) living room test room, and three hours after the start of transpiration according to the transpiration method shown in Table 1, 10 female Culex pipiens pallens Was suspended at four corners (150 cm above the ground) of the test room. The number of subsequent knockdowns over time was observed and Bliss' Probit (Prob
It asked the KT ₅₀ by it) method. Table 2 shows the results.

[Table 1]

[0084]

[Table 2] As is clear from the results shown in Table 2, all of the test agents according to the present invention show a high knockdown effect on the adult female Culex pipiens, and are practically effective even in a large space such as an 8-tatami room. Was observed. In addition, sustained efficacy was observed, and stable evaporation of the drug was obtained.

Test Example 2 Each test agent shown in Table 3 was hung on the center ceiling surface of a wagon (7.5 m ³ ), and 10 hours after the start of transpiration according to the transpiration method shown in Table 3, 10 adult Culex pipiens were introduced. The nylon net was hung by the windows of the driver's seat and rear seat of the wagon.
Observing the subsequent temporal knocked number down to obtain the KT ₅₀ by probit method Bliss. Table 4 shows the results.

[Table 3]

[0086]

[Table 4]

Test Example 3 Each test agent shown in Table 5 was hung on the center ceiling of a four-person tent (1.5 m ³ ), and three hours after the start of transpiration according to the transpiration method shown in Table 5, 10 female Culex pipiens pallens The nylon net with the garment was hung by the windows of the driver's seat and rear seat of the wagon car.
Observing the subsequent temporal knocked number down to obtain the KT ₅₀ by probit method Bliss. Table 6 shows the results.

[Table 5]

[0088]

[Table 6] As is clear from the results shown in Tables 4 and 6,
All of the test agents according to the present invention exhibited a high knockdown effect on adult female Culex pipiens, and also showed sustained efficacy, and stable evaporation of the drug was obtained.

Example 24 A 10 × 10 cm polypropylene nonwoven fabric (RW210
0, manufactured by Idemitsu Petrochemical Co., Ltd., basis weight 100 g / m ² ,
5 ml of a 1% (W / V) hexane solution of terrareslin was applied to 0.58 mm in thickness and 0.17 g / cm ³ in density, impregnated with the solution, and air-dried all day and night.
And Drug transpiration agent Y ₁ thus obtained was attached to the front surface of the blower 50 as shown in FIG. 18. FIG. 18 shows a schematic configuration of the blower 50, which is provided with an axial fan 52 on the rear side of the frame 51, and the axial fan 52 is rotated by a motor 53. Reference numeral 54 denotes an AC for driving the motor.
Power supply.

Example 25 A 4 × 5 cm polypropylene nonwoven fabric (RW2100, manufactured by Idemitsu Petrochemical Co., Ltd., basis weight 100 g / m ² , thickness 0.58 mm, density 0.17 g / cm ³ ) contained 1% of transfluthrin ( (W / V) 2 ml of a hexane solution was applied and impregnated, and air-dried all day and night was used as a chemical vaporizer (pest control agent). The thus obtained chemical evaporant Y ₂ is shown in FIG.
8 was attached to the front of the blower 50.

Test Example 4: Efficacy test by air transpiration at 8 tatami mats (33 m ³ ) The above example was placed in a 33 m ³ (3.65 m × 3.65 m × 2.5 m height) calmless room set at 25 ° C. 24, 25
Drug transpiration agent Y ₁ or Y ₂ blowing device 50 fitted with a obtained in installed in the test chamber central floor, energized to start the blower, was evaporate 1 hour. After that, Culex pipiens (Culex pi
piens pallens), a 16 mesh nylon net triangular net (20 × 20 × 16.4 height) containing 10 adult females.
cm) were hung at four corners of the room (90 × 90 cm from the wall surface) 150 cm above the ground, and exposed to the atmosphere of the drug.
The number of knockdowns over time from the exposure was observed indoors, and the KT ₅₀ was calculated by the Bliss probit method. In this test, after the end of the efficacy study one hour later, air blowing to the drug evaporator was continued as it was, and after 3,6,
The efficacy over time after 9 and 12 hours was investigated. Table 7 shows the results.

[0092]

[Table 7] As shown in Table 7 above, the chemical vaporizer (pest control agent) of the present invention exhibited a high pest control effect stably over a relatively long period of time even by blast evaporation.

Example 26 12.5 × 8 cm polypropylene nonwoven fabric (RW210
0, manufactured by Idemitsu Petrochemical Co., Ltd., basis weight 100 g / m ² ,
5 ml of a 1% (W / V) hexane solution of terrareslin was applied to 0.58 mm in thickness and 0.17 g / cm ³ in density, impregnated with the solution, and air-dried for 24 hours.
And The thus obtained drug transpiration formulation, disposable body warmer; to prepare a test preparation Z ₁ adhesion to heated evaporation type four corners with cellophane tape (13.5 × 9.5cm maximum temperature 58 ° C.).

Example 27 The vaporized chemical evaporating agent Y ₂ obtained in Example 25 was adhered to a disposable body warmer (13.5 × 9.5 cm; maximum temperature 58 ° C.) at four corners with a heat-resistant tape, and heated and evaporated. the test preparation Z ₂ was produced.

Test Example 5 Efficacy Test by Heated Evaporation As shown in FIG. 19, a fumigation test in which a lower stainless steel cylinder 61 (height 10 cm) having an inner diameter of 20 cm and an upper glass cylinder 62 (height 33 cm) were joined. The test was performed using the device 60. After test insects a (Culex) was released about 15 animals in the device, placed in test preparation Z ₁ or Z ₂ of Example 26 and 27 obtained by heating 30 minutes in advance outside the apparatus to the apparatus bottom surface, a glass plate 63 The lid was covered, fumigation was performed for 10 seconds, and the number of knockdown insects with the passage of time from the start of fumigation was observed, and KT ₅₀ was calculated by the Bliss probit method. In this test, after the effect was examined one hour later, the heating of the test agent was continued as it was, and the same test was carried out after a lapse of a predetermined time. Table 8 shows the results.

[0096]

[Table 8] As shown in Table 8 above, the chemical vaporized body (pest control agent) of the present invention stably exhibited an extremely high pest control effect over a relatively long period of time even when heated and evaporated.

[0097]

As described above, the chemical vaporizer of the present invention comprises:
A fibrous material composed of synthetic fibers and / or natural fibers is made of a fibrous material having a density of 0.05 to 1.0 g / cm ³ and a thickness of 0 so that the fibrous material has voids therein and promotes chemical evaporation. .0
Process into a sheet of 2 to 1 mm, and apply a chemical with a vapor pressure of 1 × 10 ⁻⁶ to 1 × 10 ⁻³ mmHg at 20 ° C.
Since it is impregnated and held, the amount of transpiration per unit space volume can be easily adjusted to 0.01 to 0.5 mg / hr / m ³ , and the ventilation in the holding material becomes smooth and the contact Air can release drugs into the atmosphere more efficiently.
As a result, it is possible to obtain an amount of transpiration sufficient to obtain an effective effect even with a drug having a low vapor pressure, which has been difficult to evaporate with the conventional technology, and to stabilize the drug for a long period from the initial use. Can evaporate. In addition, since the medicine holding material can be processed into various ornaments (for example, artificial flowers), it can be used for portable or indoor interiors, and product design can be drastically facilitated.

[Brief description of the drawings]

FIG. 1 is a cross-sectional view of a spherical honeycomb structure which is one embodiment of a drug holder of the present invention.

FIG. 2 is a perspective view of the spherical honeycomb structure shown in FIG.

FIG. 3 is a cross-sectional view of a spherical multiple honeycomb structure which is another embodiment of the drug support of the present invention.

FIG. 4 is a side view showing a stacked state before assembling of the spherical multilayer honeycomb structure shown in FIG. 3;

FIG. 5 is a plan view showing another embodiment of the spherical multi-layered honeycomb structure of the present invention in a state opened by 180 degrees.

FIG. 6 is a plan view showing another embodiment of the spherical multi-layer honeycomb structure of the present invention in a state opened by 180 degrees.

FIG. 7 is a perspective view of an elliptical multiple honeycomb structure which is another embodiment of the medicine holder of the present invention.

8 is a plan view showing a stacked state of the elliptical multiple honeycomb structure shown in FIG. 7 before assembly.

FIG. 9 is a side view showing a stacked state of the elliptical multiple honeycomb structure shown in FIG. 7 before assembly.

FIG. 10 is a perspective view showing an example of use of the elliptical multiple honeycomb structure shown in FIG.

FIG. 11 is a plan view showing a laminated state before assembling of another embodiment of the elliptical multiple honeycomb structure of the present invention.

FIG. 12 is a plan view showing a stacked state of another embodiment of the elliptical multiple honeycomb structure of the present invention before assembly.

FIG. 13 is a schematic configuration diagram showing one embodiment of a drug evaporation device using the drug holder of the present invention.

FIG. 14 is a schematic configuration diagram of a vibration device used in the drug evaporation device shown in FIG.

FIG. 15 is a partially broken schematic perspective view showing an embodiment of a forced vaporization type drug evaporation device using the drug holding body of the present invention.

FIG. 16 is a partially broken schematic perspective view showing another embodiment of a forced vaporization type drug evaporation device using the drug holder of the present invention.

FIG. 17 is a schematic perspective view showing an embodiment of a drug evaporating apparatus of the automatic winding roll screen type using the drug holder of the present invention.

FIG. 18 is a schematic configuration diagram of a blowing device used in Test Example 4.

FIG. 19 is a schematic configuration diagram of a cylinder fumigation test device used in Test Example 5.

[Explanation of symbols]

1,1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h
Honeycomb structure 2 Cell wall 3 Cell 4, 4a, 4b, 4c, 4d, 4e, 4f, 4h Outer layer 5, 5a, 5b, 5c, 5d, 5e, 5f, 5h Inner layer 6, 6a, 6b, 6c, 6d, 6e, 6f, 6h, 1
1,14 voids 7, 7a, 7b, 7c, 7d, 7e, 7f, 8, 8a,
8b, 8c, 8f Support sheet 13 Intermediate layer 15 Grasping part 16 Elastic linear member 19 Vent hole 20 Notch 21 Drive unit 23 Pendulum 25 Electromagnet 30 Fan 31 Blade 32 Blade fixing member 33 Rotating plate 35 Motor 40 Automatic winding roll Screen-type drug vaporizer 41 Hollow cylindrical body 43 Ratchet release button 45 Drug holder 50 Blower 60 Cylinder fumigation test device A Adhesive part S Internal space X Center axis Y Drug vaporizer Z Disposable body warmer with drug vaporizer adhered Reagent

Continued on the front page F term (reference) 2B121 AA11 AA12 CA02 CA03 CA42 CA43 CA52 CA53 CA64 CC02 CC22 CC25 EA01 EA08 EA09 FA02 FA15 4H011 AC01 AC02 AC06 BB15 BC19 DA07 DC10 DD05 DE04 DE17 DH02 DH09

Claims (5)

[Claims] 1. A medicine holding material obtained by processing a fibrous material composed of synthetic fibers and / or natural fibers to a density of 0.05 to 1.0 g / cm ³ and a thickness of 0.02 to 1 mm. A medicine having a pressure of 1 × 10 ⁻⁶ to 1 × 10 ⁻³ mmHg is held, and the amount of transpiration per unit space volume is 0.01 to 0.
A drug evaporator characterized by being adjusted to 5 mg / hr / m ³ . 2. The drug holding material is processed into a nonwoven fabric and / or a woven / knitted material and / or a paper.
A drug evaporator according to the above. 3. The transpiration area per unit space volume of the drug holding material is 5 × 10 ⁰ to 1 × 10 ³ cm ² / m ³ , and the drug transpiration method is a natural transpiration method. Item 1
Or a drug evaporative according to 2. 4. The method according to claim 1, wherein the transpiration area per unit space volume of the drug holding material is 5 × 10 ^-1 to 1 × 10 ² cm ² / m ³ , and the method of transpiration of the drug is a blowing method. Item 8. The agent for evaporating a drug according to Item 1 or 2. 5. The drug vaporizer according to claim 1, wherein the drug is an insecticide and / or a repellent.